Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Lilly Loses Approval for Covid Therapy as Omicron Spreads (1)

Nov. 30, 2022, 9:22 PM

US regulators said Wednesday that Eli Lilly & Co.’s monoclonal antibody treatment for Covid-19 is no longer authorized for emergency use because it’s not likely to work against infections caused by the forms of omicron that are dominant across the country.

The Food and Drug Administration warned earlier this month that Lilly’s drug bebtelovimab was unlikely to work against omicron subvariants BQ.1 and BQ.1.1 that were starting to gain ground across the US. Those mutations have since grown to account for more than 57% of Covid infections throughout the country, according to Centers for Disease Control and Prevention data ...